{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:39:16Z","timestamp":1794490756259,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Wider use of clozapine, one of the most effective antipshychotic drugs, is precluded by its propensity to cause agranulocytosis. Currently, clozapine is used for treatment-resistant schizophrenia, with mandatory blood count monitoring for the duration of treatment. Agranulocytosis occurs in up to 0.8% of patients and presents a significant medical challenge, despite decreasing mortality rates. In this paper, we review the epidemiology of clozapine-induced agranulocytosis (CLIA), advances in identifying genetic risk factors, and the preventive measures to reduce the risk of CLIA. We discuss the pathogenesis of CLIA, which, despite receiving considerable scientific attention, has not been fully elucidated. Finally, we address the clinical management and suggest the approach to clozapine re-challenge in patients with a previous episode of neutropenia. With a significant proportion of clozapine recipients in Western hemisphere being Black, we comment on the importance of recognizing benign ethnic neutropenia as a potential impediment to clozapine administration. This review aims to aid haematologists and psychiatrists to jointly manage neutropenia and agranulocytosis caused by clozapine.<\/jats:p>","DOI":"10.1007\/s00277-020-04215-y","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:02:19Z","timestamp":1597881739000},"page":"2477-2482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Clozapine-induced agranulocytosis"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-2640","authenticated-orcid":false,"given":"Aleksandar","family":"Mijovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"4215_CR1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209:385\u2013392","journal-title":"Br J Psychiatry"},{"key":"4215_CR2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","volume":"324","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324:746\u2013754","journal-title":"N Engl J Med"},{"key":"4215_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00606409","volume":"11","author":"J Idanpaan-Heikkila","year":"1977","unstructured":"Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193\u2013198","journal-title":"Eur J Clin Pharmacol"},{"key":"4215_CR4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"4215_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","volume":"29","author":"JL Kennedy","year":"2014","unstructured":"Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC (2014) The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 29:63\u201376","journal-title":"Int Clin Psychopharmacol"},{"key":"4215_CR6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","volume":"135","author":"R Land","year":"2017","unstructured":"Land R, Siskind D, Mcardle P et al (2017) The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135:296\u2013309","journal-title":"Acta Psychiatr Scand"},{"key":"4215_CR7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","volume":"174","author":"T Wimberley","year":"2017","unstructured":"Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990\u2013998","journal-title":"Am J Psychiatry"},{"issue":"3","key":"4215_CR8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","volume":"6","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY (2012) Balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6(3):134\u2013144","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"4215_CR9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JMJ Alvir","year":"1993","unstructured":"Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. N Engl J Med 329:162\u2013167","journal-title":"N Engl J Med"},{"key":"4215_CR10","first-page":"233","volume":"85","author":"G Lambertenghi-Deliliers","year":"2000","unstructured":"Lambertenghi-Deliliers G (2000) Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 85:233\u2013237","journal-title":"Haematologica"},{"key":"4215_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-993224","volume":"41","author":"YL Tang","year":"2008","unstructured":"Tang YL, Mao PX, Jiang F, Chen Q, Wang CY, Cai ZJ, Mitchell P (2008) Clozapine in China. Pharmacophyschiatry 41:1\u20139","journal-title":"Pharmacophyschiatry"},{"issue":"suppl.3","key":"4215_CR12","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J et al (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59(suppl.3):3\u20137","journal-title":"J Clin Psychiatry"},{"key":"4215_CR13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291719000369","volume":"50","author":"X-H Li","year":"2020","unstructured":"Li X-H, Zhong X-M, Lu L, Zheng W, Wang SB, Rao WW, Wang S, Ng CH, Ungvari GS, Wang G, Xiang YT (2020) The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med 50:583\u2013594","journal-title":"Psychol Med"},{"key":"4215_CR14","volume-title":"The drug etiology of agranulocytosis and aplastic anaemia","author":"DW Kaufman","year":"1991","unstructured":"Kaufman DW, Kelly JP, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anaemia. Oxford University Press Inc, New York"},{"key":"4215_CR15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","volume":"165","author":"L Ibanez","year":"2005","unstructured":"Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869\u2013874","journal-title":"Arch Intern Med"},{"key":"4215_CR16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1345\/aph.1G396","volume":"40","author":"PF Schulte","year":"2006","unstructured":"Schulte PF (2006) Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 40:683\u2013688","journal-title":"Ann Pharmacother"},{"key":"4215_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1192\/pb.bp.109.026054","volume":"35","author":"Z Latif","year":"2011","unstructured":"Latif Z, Jabbar F, Kelly BD (2011) Clozapine and blood dyscrasia. Psychiatrist 35:27\u201329","journal-title":"Psychiatrist"},{"key":"4215_CR18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.1994.03510360061038","volume":"271","author":"NS Young","year":"1994","unstructured":"Young NS (1994) Agranulocytosis. JAMA 271:935\u2013938","journal-title":"JAMA"},{"key":"4215_CR19","doi-asserted-by":"crossref","unstructured":"Stubner S, Grohman R, Engel R et al (2004) Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry (suppl 1):S70\u2013S78","DOI":"10.1055\/s-2004-815513"},{"key":"4215_CR20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro J, O\u2019Sullivan D, Andrews C et al (1999) Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 175:576\u2013580","journal-title":"Br J Psychiatry"},{"key":"4215_CR21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","volume":"86","author":"JJ Yunis","year":"1995","unstructured":"Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ (1995) HLA associations in clozapine-induced agranulocytosis. Blood 86:1177\u20131183","journal-title":"Blood"},{"key":"4215_CR22","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V86.10.3835.bloodjournal86103835","volume":"86","author":"D Corzo","year":"1995","unstructured":"Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ (1995) The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86:3835\u20133840","journal-title":"Blood"},{"key":"4215_CR23","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1182\/blood.V89.11.4167","volume":"89","author":"D Turbay","year":"1997","unstructured":"Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, Yunis EJ (1997) Tumor necrosis factor constellation polymorphisms and clozapine-induced agranulocytosis in two different ethnic groups. Blood 89:4167\u20134174","journal-title":"Blood"},{"key":"4215_CR24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4088\/JCP.09m05527yel","volume":"72","author":"MC Athanasiou","year":"2011","unstructured":"Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR (2011) Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 72:458\u2013463","journal-title":"J Clin Psychiatry"},{"key":"4215_CR25","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/mp.2016.97","volume":"22","author":"SE Legge","year":"2017","unstructured":"Legge SE, Hamshere ML, Ripke S et al (2017) Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 22:1502\u20131508","journal-title":"Mol Psychiatry"},{"key":"4215_CR26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/pgs-2018-0188","volume":"20","author":"SE Legge","year":"2019","unstructured":"Legge SE, Walters JTR (2019) Genetics of clozapine-associated neutropenia: recent advances, challenges, and future perspectives. Pharmacogenomics 20:279\u2013290","journal-title":"Pharmacogenomics"},{"issue":"suppl.1","key":"4215_CR27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00002018-199200071-00007","volume":"7","author":"SL Gerson","year":"1992","unstructured":"Gerson SL, Meltzer H (1992) Mechanisms of clozapine-induced agranulocytosis. Drug Saf 7(suppl.1):17\u201325","journal-title":"Drug Saf"},{"issue":"suppl.1","key":"4215_CR28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2165\/00002018-199200071-00008","volume":"7","author":"P Veys","year":"1992","unstructured":"Veys P, Wilkes S, Shah S et al (1992) Clinical experience of clozapine-induced neutropenia in the UK. Drug Saf 7(suppl.1):26\u201332","journal-title":"Drug Saf"},{"key":"4215_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(98)00110-3","volume":"131","author":"I Guest","year":"1998","unstructured":"Guest I, Sokoluk B, MacCrimmon J, Uetrecht J (1998) Examination of possible toxic and immune mechanisms of clozapine-indiced agranulocytosis. Toxicology 131:53\u201365","journal-title":"Toxicology"},{"key":"4215_CR30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2016.12.003","volume":"316","author":"F Regen","year":"2017","unstructured":"Regen F, Herzog I, Hahn E, Ruehl C, le Bret N, Dettling M, Heuser I, Hellmann-Regen J (2017) Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in vitro approach. Toxicol Appl Pharmacol 316:10\u201316","journal-title":"Toxicol Appl Pharmacol"},{"key":"4215_CR31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1994.tb04786.x","volume":"86","author":"SL Gerson","year":"1994","unstructured":"Gerson SL, Arce CY, Meltzer HY (1994) N-desmethylclozapine: a clozapine metabolite that supresses haemopoiesis. Br J Haematol 86:555\u2013561","journal-title":"Br J Haematol"},{"issue":"suppl.1","key":"4215_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00002018-199200071-00011","volume":"7","author":"JO Uetrecht","year":"1992","unstructured":"Uetrecht JO (1992) Metabolism of Clozapine by neutrophils. Drug Saf 7(suppl.1):51\u201356","journal-title":"Drug Saf"},{"key":"4215_CR33","first-page":"1375","volume":"283","author":"DP Williams","year":"1997","unstructured":"Williams DP, Pirmohamed M, Naisbitt DJ et al (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375\u20131382","journal-title":"J Pharmacol Exp Ther"},{"key":"4215_CR34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/mol.58.1.207","volume":"58","author":"DP Williams","year":"2000","unstructured":"Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK (2000) Induction of metabolism-dependent and \u2013independent neutrophil apoptosis by clozapine. Mol Pharmacol 58:207\u2013216","journal-title":"Mol Pharmacol"},{"key":"4215_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(97)00017-3","volume":"104","author":"JO Uetrecht","year":"1997","unstructured":"Uetrecht JO, Zahid N, Tehim A, Mim Fu J, Rakhit S (1997) Structural features associated with reactive metabolite formation in clozapine analogues. Chem Biol Interact 104:117\u2013129","journal-title":"Chem Biol Interact"},{"key":"4215_CR36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hup.1181","volume":"26","author":"PMM Nooijen","year":"2011","unstructured":"Nooijen PMM, Carvalho F, Flanagan RJ (2011) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychophramacol Clin Exp 26:112\u2013119","journal-title":"Hum Psychophramacol Clin Exp"},{"issue":"8","key":"4215_CR37","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.4088\/JCP.16m11152","volume":"78","author":"RS Sultan","year":"2017","unstructured":"Sultan RS, Olfson M, Correll CU, Duncan EJ (2017) Evaluating the effect of the changes in FDA guidelines for Clozapine monitoring. J Clin Psychiatry 78(8):e933\u2013e939","journal-title":"J Clin Psychiatry"},{"key":"4215_CR38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657\u2013665","journal-title":"Ann Intern Med"},{"key":"4215_CR39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1192\/bjp.188.3.255","volume":"188","author":"LR Dunk","year":"2006","unstructured":"Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188:255\u2013263","journal-title":"Br J Psychiatry"},{"key":"4215_CR40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JCP.0000000000000767","volume":"37","author":"J Lally","year":"2017","unstructured":"Lally J, Malik S, Whiskey E et al (2017) The use of Granulocyte colony-stimulating factor in clozapine rechallenge. A systematic review. J Clin Psychopharmacol 37:600\u2013604","journal-title":"J Clin Psychopharmacol"},{"key":"4215_CR41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","volume":"16","author":"O Ingimarsson","year":"2016","unstructured":"Ingimarsson O, MacCabe JH, Haraldsson M et al (2016) Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry 16:441","journal-title":"BMC Psychiatry"},{"issue":"suppl.1","key":"4215_CR42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hup.917","volume":"23","author":"RJ Flanagan","year":"2008","unstructured":"Flanagan RJ, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 23(suppl.1):27\u201341","journal-title":"Hum Psychopharmacol"},{"key":"4215_CR43","doi-asserted-by":"crossref","first-page":"e1410","DOI":"10.4088\/JCP.14m09326","volume":"76","author":"N Meyer","year":"2015","unstructured":"Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, Shergill S, MacCabe JH (2015) Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry 76:e1410\u2013e1416","journal-title":"J Clin Psychiatry"},{"key":"4215_CR44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","volume":"195","author":"S Malik","year":"2018","unstructured":"Malik S, Lally J, Ajnakina O, Pritchard M, Krivoy A, Gaughran F, Shetty H, Flanagan RJ, MacCabe JH (2018) Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophr Res 195:267\u2013273","journal-title":"Schizophr Res"},{"key":"4215_CR45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v67n0509","volume":"67","author":"RA Kanaan","year":"2006","unstructured":"Kanaan RA, Kerwin RW (2006) Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 67:756\u2013760","journal-title":"J Clin Psychiatry"},{"key":"4215_CR46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","volume":"134","author":"P Manu","year":"2012","unstructured":"Manu P, Sarpal D (2012) Muir O et al: when can patients with potentially life-threatening adverse effects be rechallenged with clozapine? Schizophr Res 134:180\u2013186","journal-title":"Schizophr Res"},{"key":"4215_CR47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","volume":"53","author":"N Myles","year":"2019","unstructured":"Myles N, Myles H, Xia S, Large M, Bird R, Galletly C, Kisely S, Siskind D (2019) A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aus NZ J Psych 53:403\u2013412","journal-title":"Aus NZ J Psych"},{"key":"4215_CR48","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2009.24.3881","volume":"28","author":"MM Hsieh","year":"2010","unstructured":"Hsieh MM, Tisdale JF, Rodgers GP, Young NS, Trimble EL, Little RF (2010) Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 28:1633\u20131637","journal-title":"J Clin Oncol"},{"key":"4215_CR49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","volume":"146","author":"MM Hsieh","year":"2007","unstructured":"Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007) Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. Ann Intern Med 146:486\u2013492","journal-title":"Ann Intern Med"},{"issue":"1","key":"4215_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000360","volume":"5","author":"D Reich","year":"2009","unstructured":"Reich D, Nalls MA, Kao WHL, Akylbekova EL, Tandon A, Patterson N, Mullikin J, Hsueh WC, Cheng CY, Coresh J, Boerwinkle E, Li M, Waliszewska A, Neubauer J, Li R, Leak TS, Ekunwe L, Files JC, Hardy CL, Zmuda JM, Taylor HA, Ziv E, Harris TB, Wilson JG (2009) Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 5(1):e1000360","journal-title":"PLoS Genet"},{"key":"4215_CR51","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.4049\/jimmunol.170.10.5244","volume":"170","author":"JS Lee","year":"2003","unstructured":"Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK, Ruzinski JT, Rhim JS, Martin TR, Goodman RB (2003) Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo. J Immunol 170:5244\u20135251","journal-title":"J Immunol"},{"key":"4215_CR52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.1988.tb01192.x","volume":"41","author":"Y Shoenfield","year":"1988","unstructured":"Shoenfield Y, Alkan ML, Asali A et al (1988) Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 41:273\u2013277","journal-title":"Eur J Haematol"},{"key":"4215_CR53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269881110364267","volume":"25","author":"E Whiskey","year":"2011","unstructured":"Whiskey E, Olofinjana O (2011) Taylor D:The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine. J Psychopharmacol 25:842\u2013845","journal-title":"J Psychopharmacol"},{"key":"4215_CR54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","volume":"174","author":"SE Legge","year":"2016","unstructured":"Legge SE, Hamshere ML, Hayes RD, Downs J, O'Donovan MC, Owen MJ, Walters JTR, MacCabe JH (2016) Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res 174:113\u2013119","journal-title":"Schizophr Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04215-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:42:34Z","timestamp":1629416554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04215-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04215-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"26 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}